Indolent systemic mastocytosis

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Kinase inhibitor 2 substances
Unknown / small molecule 1 substance
Phase II/III: 1 Phase II: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II/III

1 trial
  • Blueprint Medicines Corp. Commercial
    ELENESTINIB PHOSPHATE
    2024-516728-32-00 15 countries 2021 n=379 Orphan
    Recruiting

Phase II

2 trials
  • Blueprint Medicines Corp. Commercial
    AVAPRITINIB
    2024-512585-34-00 9 countries 2019 n=114 Orphan
    Ended
  • Telios Pharma Inc. Commercial
    1-4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE
    2024-514467-26-00 9 countries 2021 n=188
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Blueprint Medicines Corp. Commercial 2 Phase II/III, Phase II 1
Telios Pharma Inc. Commercial 1 Phase II 0
New trials by year
2019
1
2021
2
← All indication landscapes